Lantheus (LNTH) Expected to Announce Quarterly Earnings on Thursday

Lantheus (NASDAQ:LNTH) is expected to be issuing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of $1.28 per share and revenue of $363.4160 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. The firm had revenue of $92.51 million during the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. On average, analysts expect Lantheus to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $55.88 on Thursday. The firm has a market cap of $3.80 billion, a PE ratio of 14.86 and a beta of 0.09. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49. Lantheus has a 1-year low of $47.25 and a 1-year high of $118.21. The company has a fifty day moving average price of $54.22 and a 200 day moving average price of $70.73.

Insider Transactions at Lantheus

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This represents a 49.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 6,812,000 shares of company stock worth $382,427,380. 1.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. First Light Asset Management LLC acquired a new stake in Lantheus in the second quarter valued at approximately $2,459,000. Tidal Investments LLC boosted its position in Lantheus by 3.5% in the second quarter. Tidal Investments LLC now owns 16,481 shares of the medical equipment provider’s stock valued at $1,349,000 after buying an additional 558 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Lantheus by 330.5% in the second quarter. Tower Research Capital LLC TRC now owns 12,114 shares of the medical equipment provider’s stock valued at $992,000 after buying an additional 9,300 shares in the last quarter. Orion Porfolio Solutions LLC boosted its position in Lantheus by 3.9% in the second quarter. Orion Porfolio Solutions LLC now owns 10,010 shares of the medical equipment provider’s stock valued at $819,000 after buying an additional 377 shares in the last quarter. Finally, MML Investors Services LLC boosted its position in Lantheus by 23.3% in the second quarter. MML Investors Services LLC now owns 7,778 shares of the medical equipment provider’s stock valued at $637,000 after buying an additional 1,469 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Truist Financial set a $63.00 target price on shares of Lantheus and gave the stock a “hold” rating in a research note on Monday, August 11th. William Blair reaffirmed a “market perform” rating on shares of Lantheus in a research note on Wednesday, July 16th. The Goldman Sachs Group set a $77.00 target price on shares of Lantheus and gave the stock a “neutral” rating in a research note on Wednesday, October 8th. B. Riley reduced their target price on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a research note on Tuesday, September 16th. Finally, JMP Securities reduced their target price on shares of Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a research note on Thursday, August 7th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $74.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.